Advertisement
Canada markets close in 2 hours 16 minutes
  • S&P/TSX

    21,843.07
    +114.52 (+0.53%)
     
  • S&P 500

    5,054.02
    +35.63 (+0.71%)
     
  • DOW

    38,160.88
    +257.59 (+0.68%)
     
  • CAD/USD

    0.7308
    +0.0027 (+0.36%)
     
  • CRUDE OIL

    79.12
    +0.12 (+0.15%)
     
  • Bitcoin CAD

    80,729.74
    +2,495.21 (+3.19%)
     
  • CMC Crypto 200

    1,275.11
    +4.37 (+0.34%)
     
  • GOLD FUTURES

    2,311.10
    +0.10 (+0.00%)
     
  • RUSSELL 2000

    2,008.31
    +28.08 (+1.42%)
     
  • 10-Yr Bond

    4.5830
    -0.0120 (-0.26%)
     
  • NASDAQ

    15,793.25
    +187.77 (+1.20%)
     
  • VOLATILITY

    14.83
    -0.56 (-3.64%)
     
  • FTSE

    8,172.15
    +50.91 (+0.63%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6815
    +0.0022 (+0.32%)
     

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

HERCULES, Calif., April 18, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

To participate, dial 800-274-8461 within the U.S. or (+1) 203-518-9814 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418334721/en/

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com